- Home
- PHIO vs AYTU Comparison
PHIO vs AYTU Comparison
Compare PHIO & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHIO
- AYTU
- Stock Information
- Founded
- PHIO 2011
- AYTU N/A
- Country
- PHIO United States
- AYTU United States
- Employees
- PHIO N/A
- AYTU N/A
- Industry
- PHIO Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- PHIO Health Care
- AYTU Health Care
- Exchange
- PHIO Nasdaq
- AYTU Nasdaq
- Market Cap
- PHIO 8.6M
- AYTU 9.6M
- IPO Year
- PHIO N/A
- AYTU N/A
- Fundamental
- Price
- PHIO $2.16
- AYTU $2.10
- Analyst Decision
- PHIO Strong Buy
- AYTU
- Analyst Count
- PHIO 2
- AYTU 0
- Target Price
- PHIO $9.00
- AYTU N/A
- AVG Volume (30 Days)
- PHIO 703.0K
- AYTU 621.9K
- Earning Date
- PHIO 08-13-2025
- AYTU 05-14-2025
- Dividend Yield
- PHIO N/A
- AYTU N/A
- EPS Growth
- PHIO N/A
- AYTU N/A
- EPS
- PHIO N/A
- AYTU N/A
- Revenue
- PHIO N/A
- AYTU $81,659,000.00
- Revenue This Year
- PHIO N/A
- AYTU N/A
- Revenue Next Year
- PHIO N/A
- AYTU $8.68
- P/E Ratio
- PHIO N/A
- AYTU N/A
- Revenue Growth
- PHIO N/A
- AYTU 0.41
- 52 Week Low
- PHIO $0.97
- AYTU $0.95
- 52 Week High
- PHIO $9.79
- AYTU $2.96
- Technical
- Relative Strength Index (RSI)
- PHIO 50.19
- AYTU 60.77
- Support Level
- PHIO $2.11
- AYTU $1.97
- Resistance Level
- PHIO $2.30
- AYTU $2.17
- Average True Range (ATR)
- PHIO 0.21
- AYTU 0.14
- MACD
- PHIO -0.04
- AYTU 0.00
- Stochastic Oscillator
- PHIO 9.65
- AYTU 58.33
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.